← Return to Covid19 vaccine in essential thrombocythemiaDiscussion
Covid19 vaccine in essential thrombocythemiaBlood Cancers & Disorders | Last Active: Sep 3, 2021 | Replies (6)
Comment receiving replies
Replies to "I am considering a monoclonal antibody trial vaccine versus the viral vector and mRNA vaccines out...."
Hi Stillwell, are you referring to the emergency use authorization (EUA) for REGEN-COV (casirivimab and imdevimab, administered together)? This monoclonal antibody therapy is for adults and children over 12 who are at high-risk of hospitalization or death after a known exposure to someone with COVID-19.
The FDA states that:
"Prophylaxis with REGEN-COV is not a substitute for vaccination against COVID-19. FDA has authorized three vaccines to prevent COVID-19 and serious clinical outcomes caused by COVID-19, including hospitalization and death. FDA urges you to get vaccinated, if you are eligible."
Here's more information:
– FDA authorizes REGEN-COV monoclonal antibody therapy for post-exposure prophylaxis (prevention) for COVID-19 https://www.fda.gov/drugs/drug-safety-and-availability/fda-authorizes-regen-cov-monoclonal-antibody-therapy-post-exposure-prophylaxis-prevention-covid-19
It doesn't look like an either one or the other situation. Good for you for doing your research.
Can you share a link to this trial vaccine? I'm sure many would be interested to read about it. Thank you.